By Karen Roman Biopharmaceutical company ReAlta Life Sciences said it designated immunologist Laurie Glimcher, M.D., to its Board of Directors. Dr. Glimcher is renowned for her 35 years of work in cancer research, and she is the Richard and Susan...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced positive data for NPM-139, its subdermal semaglutide implant for chronic weight management, with expected once or twice-yearly dosing. The results support the company’s NanoPortal implant for delivery of therapeutic molecules for...

By Karen Roman Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) Series A financing round in Augustine Therapeutics. The founding will support Phase 2 of AGT-100216, Augustine’s main candidate for Charcot-Marie-Tooth disease...

By Daniella Parra Taiho Pharmaceutical said it will acquire Araris Biotech, a leader in antibody drug conjugates (ADCs), for an initial $400 million, with potential additional milestone payments of up to $740 million. Araris’ AraLinQ platform enhances ADC drug design,...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) implant, in the first-in-human clinical trial of its kind. The company also said it achieved full enrollment for this study, which targets...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said it expects to spin off Cortigent, Inc., its brain implant devices division, as an independent publicly-traded company. Vivani aims to create two companies focused on driving long term value creation in...

By Karen Roman Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction. Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, and has been approved for certain chronic myeloid leukemia (CML) indications and included in China’s National Reimbursement Drug List. Olverembatinib,...

By Karen Roman Medical tech company Nano-X Imaging Ltd. (Nasdaq: NNOX) said Nanox.ARC, its digital multi-source 3D tomosynthesis imaging system, received CE mark certification in the European market. Nanox.ARC also has FDA clearance for general use in the U.S. and...

By Daniella Parra Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics is a biotechnology company developing multi-payload ADCs that says it aims to...